Human leukocyte antigen A*02:01-restricted Cytomegalovirus phosphoprotein 65 peptide-MHC complex (HLA-A*02:01/CMV pp65(495-503))

The HLA-A*02:01-restricted Cytomegalovirus (CMV) phosphoprotein 65 (pp65) peptide-MHC complex is a critical immunological target consisting of the HLA-A*02:01 molecule presenting the immunodominant NLVPMVATV peptide (residues 495-503). This complex is expressed on the surface of antigen-presenting cells and CMV-infected cells, serving as a primary signal for the recognition and activation of CD8+ cytotoxic T lymphocytes. In the context of human health, this target is vital for controlling CMV latency and reactivation, particularly in immunocompromised individuals such as transplant recipients. Beyond viral infection, the pp65 protein has been detected in certain malignancies like glioblastoma, making this pMHC complex a candidate for cancer immunotherapy. Therapeutic strategies targeting this complex include adoptive T-cell therapies (TCR-T), TCR-like antibodies, and peptide-based vaccines designed to elicit a robust cellular immune response. The specificity of the interaction between the T-cell receptor and this pMHC complex is a cornerstone of precision immunotherapy for CMV-related pathologies.

Other names

HLA-A*02:01-NLVPMVATV complexCMV pp65 A2 complexpMHC HLA-A*02:01/NLVPMVATVCytomegalovirus pp65(495-503) peptide-HLA-A*02:01 complexCMV pp65-MHC Class I complex

T-cell receptor (TCR) binding and activation, T-cell mediated lysis of infected or tumor cells, Adoptive cellular immunotherapy